Standard Biotools (LAB) Total Liabilities (2010 - 2026)

Standard Biotools (LAB) has 17 years of Total Liabilities data on file, last reported at $78.0 million in Q1 2026.

• Quarterly Total Liabilities fell 37.61% year-over-year to $78.0 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $78.0 million (down 37.61% YoY) and the FY2025 annual result came in at $143.5 million, up 2.02% from the prior year.
• Total Liabilities declined to $78.0 million in Q1 2026 per LAB's latest filing, from $143.5 million in the prior quarter.
• Across five years, Total Liabilities topped out at $249.8 million in Q1 2022 and bottomed at $78.0 million in Q1 2026.
• The 5-year median for Total Liabilities is $159.8 million (2023), against an average of $160.6 million.
• The widest annual swing landed in 2022, when Total Liabilities soared 37.07%; it then sank 37.61% in 2025.
• Tracing LAB's Total Liabilities over 5 years: stood at $160.5 million in 2022, then fell by 0.41% to $159.9 million in 2023, then dropped by 12.04% to $140.6 million in 2024, then advanced by 2.02% to $143.5 million in 2025, then slumped by 45.64% to $78.0 million in 2026.
• Per Business Quant, the three latest LAB Total Liabilities figures stand at $78.0 million (Q1 2026), $143.5 million (Q4 2025), and $140.0 million (Q3 2025).

Peer Comparison